-
NMPA Announcement on Including the Testing Methods for Azelaic Acid and Its Salts in Cosmetics and Other 5 Testing Methods into the Technical Specification for the Safety of Cosmetics (Edition 2015) (No. 45, 2024)
2025-02-19
The National Medical Products Administration (NMPA) has organized to formulate Testing Methods for Azelaic Acid and Its Salts in Cosmetics and other 5 testing methods, which have been reviewed and approved by the Chairman's Meeting of the NMPA's Cosmetic Standardization Technical Committee.
-
NMPA Re-elected as a Member of the ICH Management Committee
2025-02-19
On June 4, 2024, the plenary session of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) was held in Fukuoka, Japan, at which the National Medical Products Administration (NMPA) was elected as a member of the ICH Management Committee for the third time.
-
Sulbactam Sodium for Injection/Durlobactam Sodium for Injection (co-packaged) Approved for Marketing by China NMPA
2025-02-19
Recently, the Category 1 innovative drug, Sulbactam Sodium for Injection/Durlobactam Sodium for Injection (co-packaged) (trade name: 鼎优乐/XACDURO) of Entasis Therapeutics, Inc. is approved for marketing through the priority review and approval procedure by China NMPA.
-
Ivonescimab Injection Approved for Marketing by China NMPA
2025-02-19
Recently, the Ivonescimab Injection (trade name: 依达方) of Akeso Inc. is approved for marketing through the priority review and approval procedure by China NMPA.
-
Rilertinib Mesylate Tablets Approved for Marketing by China NMPA
2025-02-19
Recently, the Category 1 innovative drug Rilertinib Mesylate Tablets (trade name: 圣瑞沙) of Nanjing Sanhome Pharmaceutical Limited Company is approved for marketing by China NMPA.
-
Envonalkib Citrate Capsules Approved for Marketing by China NMPA
2025-02-19
Recently, the Category 1 innovative drug Envonalkib Citrate Capsules (trade name: 安洛晴) of Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is approved for marketing by China NMPA.
